Evidence map›Paper›PMID 39581430›Full record

Trial reportHeart rhythm2025

Risk of recurrent ventricular tachyarrhythmia following the occurrence of a first ventricular arrhythmic event in patients with a primary prevention implantable cardioverter-defibrillator.

Matthew Wang, Ilan Goldenberg, Arwa Younis, Ido Goldenberg, Michael Christof, David T Huang, Scott McNitt, Bronislava Polonsky, Valentina Kutyifa, Wojciech Zareba and 2 more

Abstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Heart rhythm, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Matthew WangClinical Cardiovascular Research Center, University of Rochester, Rochester, New York.
Ilan GoldenbergClinical Cardiovascular Research Center, University of Rochester, Rochester, New York.
Arwa YounisClinical Cardiovascular Research Center, University of Rochester, Rochester, New York.
Ido GoldenbergClinical Cardiovascular Research Center, University of Rochester, Rochester, New York.
Michael ChristofClinical Cardiovascular Research Center, University of Rochester, Rochester, New York.
David T HuangClinical Cardiovascular Research Center, University of Rochester, Rochester, New York.
Scott McNittClinical Cardiovascular Research Center, University of Rochester, Rochester, New York.
Bronislava PolonskyClinical Cardiovascular Research Center, University of Rochester, Rochester, New York.
Valentina KutyifaClinical Cardiovascular Research Center, University of Rochester, Rochester, New York.
Wojciech ZarebaClinical Cardiovascular Research Center, University of Rochester, Rochester, New York.
Amole OjoClinical Cardiovascular Research Center, University of Rochester, Rochester, New York.
Mehmet K AktaşClinical Cardiovascular Research Center, University of Rochester, Rochester, New York. Electronic address: mehmet_aktas@urmc.rochester.edu.

Funding

Late Sodium Current Blockade in High-Risk ICD Patients - CCC - Lead ApplicationU01HL096607 · NHLBI · UNIVERSITY OF ROCHESTER · PI ZAREBA, WOJCIECH · 2010 to 2015
$5.9M
Late Sodium Current Blockade in High-Risk ICD Patients - DCCU01HL096610 · NHLBI · UNIVERSITY OF ROCHESTER · PI ZAREBA, WOJCIECH · 2010 to 2015
$3.4M
Risk Stratification in MADIT II Type PatientsR01HL077478 · NHLBI · UNIVERSITY OF ROCHESTER · PI ZAREBA, WOJCIECH · 2005 to 2008
$2.7M
NHLBI NIH HHS R01 HL077478NHLBI NIH HHS U01 HL096607NHLBI NIH HHS U01 HL096610
6 · The paper itself

Abstract

backgroundThere are limited data on clinical and arrhythmic outcomes after a first ventricular tachyarrhythmia (VTA) in heart failure (HF) patients who receive a primary prevention implantable cardioverter-defibrillator (ICD).

objectiveThis study was designed to quantify the burden of and to identify risk factors for recurrent VTA in this population and to evaluate the risk of all-cause mortality associated with recurrent VTA.

methodsThe study comprised 789 patients who experienced VTA following primary prevention ICD implantation in 5 ICD trials (MADIT-II, MADIT-RISK, MADIT-CRT, MADIT-RIT, RAID). Landmark analysis was used to quantify the burden and to identify predictors of recurrent VTA. Time-dependent analysis was used to evaluate the association of VTA recurrence with subsequent mortality.

resultsThe mean age of the study patients was 63 years, and 17% were women. The cumulative probability of experiencing at least 1 recurrent VTA episode at 3 years after a first VTA episode was 60%; the recurrent VTA burden after a first event during 3 years was 2.8 episodes per patient. The risk of recurrent VTA remained ≥56% at 3 years regardless of baseline clinical and echocardiographic risk factors. VTA recurrence was associated with a significant 2-fold increased risk of subsequent all-cause mortality.

conclusionPatients with a primary prevention ICD who experience an episode of VTA are at high risk of recurrent VTA, regardless of baseline risk factors. Recurrent VTA is associated with a pronounced increase in the risk of death. These findings suggest a need for early intervention after a first VTA in patients who receive a primary prevention ICD.

Indexed as

Death, Sudden, CardiacDefibrillators, ImplantableHeart FailurePrimary PreventionTachycardia, VentricularAgedFemaleFollow-Up StudiesHumansMaleMiddle AgedRecurrenceRisk AssessmentRisk FactorsAblationHeart failureImplantable cardioverter-defibrillatorVentricular fibrillationVentricular tachycardia

Identifiers

PMID39581430
PMCPMC12095602

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.